These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 25920748)

  • 1. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.
    Hu Y; Bobb D; He J; Hill DA; Dome JS
    Cancer Biol Ther; 2015; 16(6):949-57. PubMed ID: 25920748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Major Heat Shock Proteins, Hsp70 and Hsp90, in 2-Methoxyestradiol-Mediated Osteosarcoma Cell Death Model.
    Gorska-Ponikowska M; Kuban-Jankowska A; Marino Gammazza A; Daca A; Wierzbicka JM; Zmijewski MA; Luu HH; Wozniak M; Cappello F
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.
    Hertlein E; Wagner AJ; Jones J; Lin TS; Maddocks KJ; Towns WH; Goettl VM; Zhang X; Jarjoura D; Raymond CA; West DA; Croce CM; Byrd JC; Johnson AJ
    Blood; 2010 Jul; 116(1):45-53. PubMed ID: 20351313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models.
    Fischer-Mertens J; Otte F; Roderwieser A; Rosswog C; Kahlert Y; Werr L; Hellmann AM; Berding M; Chiu B; Bartenhagen C; Fischer M
    Cell Oncol (Dordr); 2022 Oct; 45(5):991-1003. PubMed ID: 35953764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing Magnetic Hyperthermia Efficacy through Targeted Heat Shock Protein 90 Inhibition: Unveiling Immune-Mediated Therapeutic Synergy in Glioma Treatment.
    Gupta R; Chauhan A; Kaur T; Kuanr BK; Sharma D
    ACS Nano; 2024 Jul; 18(26):17145-17161. PubMed ID: 38906828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.
    Akiyama M; Hideshima T; Shammas MA; Hayashi T; Hamasaki M; Tai YT; Richardson P; Gryaznov S; Munshi NC; Anderson KC
    Cancer Res; 2003 Oct; 63(19):6187-94. PubMed ID: 14559802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.
    Hu ZY; Lu J; Zhao Y
    Br J Pharmacol; 2014 Jun; 171(11):2778-89. PubMed ID: 24471734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of telomerase activity and induction of apoptosis by Rhodospirillum rubrum L-asparaginase in cancer Jurkat cell line and normal human CD4+ T lymphocytes.
    Zhdanov DD; Pokrovsky VS; Pokrovskaya MV; Alexandrova SS; Eldarov MA; Grishin DV; Basharov MM; Gladilina YA; Podobed OV; Sokolov NN
    Cancer Med; 2017 Nov; 6(11):2697-2712. PubMed ID: 28984046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perifosine as a potential novel anti-telomerase therapy.
    Holohan B; Hagiopian MM; Lai TP; Huang E; Friedman DR; Wright WE; Shay JW
    Oncotarget; 2015 Sep; 6(26):21816-26. PubMed ID: 26307677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease.
    Ait-Aissa K; Ebben JD; Kadlec AO; Beyer AM
    Pharmacol Res; 2016 Sep; 111():422-433. PubMed ID: 27394166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of imetelstat, a first-in-class oligonucleotide telomerase inhibitor.
    González-Sales M; Lennox AL; Huang F; Pamulapati C; Wan Y; Sun L; Berry T; Kelly Behrs M; Feller F; Morcos PN
    CPT Pharmacometrics Syst Pharmacol; 2024 Jul; 13(7):1264-1277. PubMed ID: 38771074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia.
    Bruedigam C; Porter AH; Song A; Vroeg In de Wei G; Stoll T; Straube J; Cooper L; Cheng G; Kahl VFS; Sobinoff AP; Ling VY; Jebaraj BMC; Janardhanan Y; Haldar R; Bray LJ; Bullinger L; Heidel FH; Kennedy GA; Hill MM; Pickett HA; Abdel-Wahab O; Hartel G; Lane SW
    Nat Cancer; 2024 Jan; 5(1):47-65. PubMed ID: 37904045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ortho-Quinone tanshinones directly inhibit telomerase through an oxidative mechanism mediated by hydrogen peroxide.
    Soares J; Keppler BR; Wang X; Lee KH; Jarstfer MB
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7474-8. PubMed ID: 22044621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Author Correction: DCZ5248, a novel dual inhibitor of Hsp90 and autophagy, exerts antitumor activity against colon cancer.
    Chen XL; Liu P; Zhu WL; Lou LG
    Acta Pharmacol Sin; 2024 Mar; 45(3):660. PubMed ID: 38012293
    [No Abstract]   [Full Text] [Related]  

  • 15. ATRX represses alternative lengthening of telomeres.
    Napier CE; Huschtscha LI; Harvey A; Bower K; Noble JR; Hendrickson EA; Reddel RR
    Oncotarget; 2015 Jun; 6(18):16543-58. PubMed ID: 26001292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Common Cancer Risk-Associated Allele in the hTERT Locus Encodes a Dominant Negative Inhibitor of Telomerase.
    Killedar A; Stutz MD; Sobinoff AP; Tomlinson CG; Bryan TM; Beesley J; Chenevix-Trench G; Reddel RR; Pickett HA
    PLoS Genet; 2015 Jun; 11(6):e1005286. PubMed ID: 26053551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomere G-Quadruplex as a Potential Target to Accelerate Telomere Shortening by Expanding the Incomplete End-Replication of Telomere DNA.
    Tan Z; Tang J; Kan ZY; Hao YH
    Curr Top Med Chem; 2015; 15(19):1940-6. PubMed ID: 25980416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Hsp90 Level as a Marker of Early Acute Lymphoblastic Leukemia Engraftment and Progression in Mice.
    Milani M; Laranjeira AB; de Vasconcellos JF; Brandalise SR; Nowill AE; Yunes JA
    PLoS One; 2015; 10(6):e0129298. PubMed ID: 26068922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of hTERT/telomerase contributes to the antitumor activity of pristimerin in pancreatic ductal adenocarcinoma cells.
    Deeb D; Gao X; Liu Y; Pindolia K; Gautam SC
    Oncol Rep; 2015 Jul; 34(1):518-24. PubMed ID: 25997419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy.
    Cheng W; Ainiwaer A; Xiao L; Cao Q; Wu G; Yang Y; Mao R; Bao Y
    Mol Med Rep; 2015 Aug; 12(2):2451-6. PubMed ID: 25955495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.